News
PEN
320.91
+0.04%
0.14
Penumbra (PEN) Gets a Hold from UBS
TipRanks · 3d ago
Weekly Report: what happened at PEN last week (1102-1106)?
Weekly Report · 11/09 09:31
Penumbra (PEN), Why Is Its Latest Update Drawing Attention?
Simply Wall St · 11/08 13:33
How Third Quarter Earnings Will Impact Penumbra Stock Investors
Simply Wall St · 11/06 07:31
Weekly Report: what happened at PEN last week (1026-1030)?
Weekly Report · 11/02 09:31
Penumbra (PEN) Reports Q3 Growth And FDA Clearance, Is The Upside Already Priced In?
Simply Wall St · 11/01 12:31
Penumbra (PEN) Q3 Results Spotlight Profit Pressure Beneath Premium Valuation
Simply Wall St · 10/31 00:30
Did FDA Clearance For DVT Treatment Just Shift Penumbra (PEN) Investment Narrative?
Simply Wall St · 10/30 06:40
Penumbra, Inc. Reports Third Quarter 2026 Revenue of $410.1 million
NASDAQ · 10/30 06:28
Press Release: Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Dow Jones · 10/29 20:05
Boston Scientific price target lowered to $49 from $54 at Bernstein
TipRanks · 10/29 13:06
Weekly Report: what happened at PEN last week (1019-1023)?
Weekly Report · 10/26 09:31
How DVT Clearance At Penumbra Stock Has Changed Its Investment Story
Simply Wall St · 10/22 17:37
Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results
Benzinga · 10/20 13:04
Weekly Report: what happened at PEN last week (1012-1016)?
Weekly Report · 10/19 09:31
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
Seeking Alpha · 10/15 17:27
Weekly Report: what happened at PEN last week (1005-1009)?
Weekly Report · 10/12 09:33
Will Wearable Recovery Data Change Penumbra Stock Narrative
Simply Wall St · 10/09 22:26
Can Penumbra (PEN) Justify Its Valuation As STORM PE Data Strengthens Its Recovery Story?
Simply Wall St · 10/08 15:31
Penumbra’s CAVT device shows efficacy in pulmonary embolism
TipRanks · 10/06 13:15
More
Webull provides a variety of real-time PEN stock news. You can receive the latest news about Penumbra Inc through multiple platforms. This information may help you make smarter investment decisions.
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.